Literature DB >> 9088579

Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans.

B B Rasmussen1, K Brøsen.   

Abstract

AIMS: The cytochrome P4501A2 (CYP1A2) catalyses the metabolism of a number of clinically used drugs, and thus there is an interest in determining the activity of CYP1A2 in patients before treatment with CYP1A2 substrates. Caffeine is the most commonly used model drug to assess CYP1A2 function, but due to the complex metabolism of caffeine, there is a need for an alternative drug to use as an index of CYP1A2 activity. In this study the CYP1A2 substrate theophylline was tested as a possible alternative to caffeine as a model drug for CYP1A2.
METHODS: Twelve healthy volunteers ingested 200 mg of caffeine, and the caffeine metabolic ratios (CMR), CMRurine = (AFMU + 1MX + 1MU)/17DMU and CMRplasma = 17DMX/137TMX were determined 6 h after drug intake. After a period of about 2 months the volunteers ingested 257 mg theophylline and blood samples were drawn and urine was collected during the following 48 h. The oral and partial clearance of theophylline were calculated via N-demethylation and 8-hydroxylation. The theophylline metabolic ratios, 1MU/13DMX and 3MX/13DMX being evaluated as indices of CYP1A2 catalysed N-demethylation and 13DMU/13DMX as an index of partly CYP1A2 catalysed 8-hydroxylation, were estimated in 0-12 h, 0-24 h and 0-48 h urine samples, and in plasma and spot urine samples 6 h after the intake of theophylline.
RESULTS: The theophylline plasma ratios for the N-demethylation pathways correlated with the oral clearance of theophylline (rs = 0.881-0.934, P < 0.001) and with the respective formation clearances of the metabolites (rs = 0.712-0.925, P < 0.05). Furthermore, all of the theophylline plasma ratios correlated with the caffeine plasma ratio (rs = 0.645-0.663, P < 0.05). None of the caffeine metabolic ratios and none of the 6 h urinary theophylline ratios correlated with the oral or the partial clearances of theophylline (rs = 0.042-0.556, P < 0.05). The theophylline 0-12 h urine ratios correlated with the oral clearance of theophylline (rs = 0.677-0.757, P < 0.05) and with the respective formation clearances of the metabolites (rs = 0.705-0.750, P < 0.05). However, none of the theophylline urine ratios correlated with any of the caffeine metabolic ratios.
CONCLUSIONS: In summary the theophylline 6 h plasma and 0-12 h urine ratios 1MU/13DMX and 3MX/13DMX, both reflecting N-demethylation seem to be predictors of the CYP1A2 mediated metabolism of theophylline, whereas only the plasma ratio correlated with the caffeine plasma 17DMX/13TMX ratio. Thus, it would appear that the plasma theophylline N-demethylation ratios are superior to the urine ratios as indices of CYP1A2 activity. However, because in some individuals the concentrations of theophylline metabolites in plasma were close to the limit of detection, it is concluded that theophylline does not have marked advantages over caffeine as a model drug for assessing CYP1A2 activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9088579      PMCID: PMC2042742          DOI: 10.1111/j.1365-2125.1997.00546.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.

Authors:  P Damkier; L L Hansen; K Brosen
Journal:  Br J Clin Pharmacol       Date:  1999-12       Impact factor: 4.335

2.  Tacrine is not an ideal probe drug for measuring CYP1A2 activity in vivo.

Authors:  J T Larsen; L L Hansen; K Brosen
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

3.  Macrolide-theophylline interactions: no role for the inhibition of cytochrome P4501A2.

Authors:  Thomas M Polasek; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2008-12       Impact factor: 4.335

Review 4.  Impact of obesity on drug metabolism and elimination in adults and children.

Authors:  Margreke J E Brill; Jeroen Diepstraten; Anne van Rongen; Simone van Kralingen; John N van den Anker; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2012-05-01       Impact factor: 6.447

5.  Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers.

Authors:  Laurence Gabriel; Michel Tod; Sylvain Goutelle
Journal:  Clin Pharmacokinet       Date:  2016-08       Impact factor: 6.447

6.  Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test.

Authors:  A C Parker; P Pritchard; T Preston; I Choonara
Journal:  Br J Clin Pharmacol       Date:  1998-02       Impact factor: 4.335

7.  Phenotype-genotype analysis of CYP1A2 in Japanese patients receiving oral theophylline therapy.

Authors:  Keiji Takata; Junji Saruwatari; Naoyuki Nakada; Mizuna Nakagawa; Koichiro Fukuda; Fujiho Tanaka; Shinobu Takenaka; Shuichi Mihara; Toru Marubayashi; Kazuko Nakagawa
Journal:  Eur J Clin Pharmacol       Date:  2005-12-30       Impact factor: 2.953

8.  Effect of daidzein on CYP1A2 activity and pharmacokinetics of theophylline in healthy volunteers.

Authors:  Wen-Xing Peng; Huan-De Li; Hong-Hao Zhou
Journal:  Eur J Clin Pharmacol       Date:  2003-05-17       Impact factor: 2.953

9.  A cytochrome P450 phenotyping cocktail causing unexpected adverse reactions in female volunteers.

Authors:  Rasmus Steen Pedersen; Per Damkier; Mette Marie Hougaard Christensen; Kim Brosen
Journal:  Eur J Clin Pharmacol       Date:  2013-08-06       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.